Cardiff Oncology, Inc. (CRDF)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$1.05-4.55%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — stabilize or grow revenue from 2027: metric not reported.
Cardiff Oncology aims to share detailed Phase 2 CRDF-004 data and registrational plans. The company is addressing litigation with Nerviano Medical Sciences and undergoing leadership restructuring. Analysts expect revenue of $229.6M in 2026 despite losses. The new CEO may stabilize operations and advance drug development.
Revenue is expected to decline nearly 50% next year to $189.3M. The company remains unprofitable with negative EPS around -$0.69 in 2026. Ongoing litigation and leadership changes create uncertainty. The recent 30% share price drop reflects these risks.
The market prices in about -50% revenue growth and continued losses through 2026. Our fair value of $0.23 matches consensus estimates, implying limited upside absent positive catalysts. The market likely undervalues optionality but prices in high risk.
Breaks if: continued leadership turnover or unclear strategy by end 2026
Implement leadership changes and organizational restructuring to support clinical and operational execution.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has a mixed management execution track record, which adds uncertainty to its long-term prospects.
The market seems to price in a high level of fragility due to the company's expensive valuation relative to peers. There is an expectations gap, suggesting that investors may be anticipating significant future improvements.
Fundamentals are likely to remain under pressure in the near term, given the company's recent earnings miss and ongoing litigation. However, management is making strides in advancing its clinical trials, which could provide some positive momentum.
The long-term thesis hinges on the outcomes of the Phase 3 trial for onvansertib and the resolution of ongoing litigation. Additionally, the performance of sector bellwethers and overall market conditions will be crucial in determining CRDF's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The primary reason is that CRDF's financial performance dropped significantly. It fell from the robust half to the weak half of its sector. Additionally, William Blair downgraded CRDF to a Hold, which may affect investor sentiment.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. The company completed key leadership appointments including a new CEO, CFO, and COO in early 2026 to support execution. This restructuring aligns with management's stated focus and is delivering organizational changes.
“Leadership additions position Company to execute on key upcoming clinical and regulatory milestones”
“Appointed Mani Mohindru as President and CEO, Josh Muntner as CFO, and Ajay Aggarwal as COO”
Breaks if: litigation unresolved or adverse rulings by end 2026
Breaks if: no detailed Phase 2 data or registrational plans shared by end 2026
Breaks if: revenue declines more than 10% in 2027 vs 2026
Over the next 1 to 3 years, CRDF's performance will depend on its ability to navigate challenges while leveraging sector momentum. Not investment advice.